BioCryst, Presidio in All-Stock Deal; Form HCV Powerhouse
BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., will acquire Presidio Pharmaceuticals Inc., of San Francisco, in an all-stock transaction valued at about $101 million, creating a new company centered on hepatitis C virus (HCV) and rare disease hereditary angioedema (HAE).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter